Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration
Bayer and discovery outfit Evotec have long been bosom buddies, cycling through partnerships for the better part of a decade. But now, Bayer is dumping rights to a cough drug out of that collaboration, citing dwindling returns on a competitive market.
Bayer has discontinued development of eliapixant and will hand back full rights to the drug to Evotec after the German drug giant “concluded that the overall benefit no longer outweighs the risk in the actively pursued indications,” according to a release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.